Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796160 | 0.85 | LMNA (0.46) | KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL17581276 | 0.78 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17589013 | 0.77 | LMNA (0.33) | KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30961378 | 0.76 | MAPKAPK2 (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30961293 | 0.76 | LMNA (0.35) | KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL17581324 | 0.76 | MAPKAPK2 (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24046148 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30961423 | 0.74 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30238970 | 0.74 | NOS3 (0.36) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4579208 | 0.74 | NOS3 (0.36) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | KDM4E 4782/4885ALDH1A1 566/4885SMN1; SMN2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.